• Cinoxacin in Cell and Gram-Negative Assays

  2026-08-13

  Learn how Cinoxacin (SKU BA1045) can clarify antimicrobial effects in bacterial, host-cell, and coculture experiments without confusing bacterial suppression with mammalian cytotoxicity. The article provides scenario-based guidance on solvent controls, MIC interpretation, assay compatibility, and practical product selection.

• ISG20 Atherosclerosis: From Causality to Imaging

  2026-08-12

  A translational framework for connecting genetic evidence, macrophage biology, plaque localization, and fluorescence detection using the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody.

• Amyloid Beta-peptide (25-35): Assay Design

  2026-08-12

  Amyloid Beta-peptide (25-35) is a focused tool for modeling mitochondrial stress, oxidative injury, aggregation, and microglial signaling. This guide presents a pathway-aware assay framework that connects Aβ25-35 exposure to the FLOT1–FOSL2–EphA2 axis without overstating what a short peptide model can represent.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-08-11

  Gu et al. show that palbociclib alone can restrain pancreatic tumor-cell growth while unexpectedly enhancing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies BET inhibition with JQ1 as a means of reversing this phenotype through coordinated regulation of GSK3β-mediated Wnt/β-catenin and TGF-β/Smad signaling.

• Mupirocin and Novobiocin Activity in Canine Staphylococci

  2026-08-10

  Fulham and colleagues compared mupirocin and novobiocin susceptibility in meticillin-susceptible and meticillin-resistant staphylococci recovered from healthy dogs and dogs with superficial pyoderma. The study’s main contribution is its clinically relevant comparison of resistance groups and specimen populations, showing preserved mupirocin activity but more variable novobiocin susceptibility among resistant isolates.

• LY2109761: Mapping TGF-β Signaling in Stemness

  2026-08-09

  LY2109761 is a TGF-β receptor type I and II dual inhibitor for dissecting receptor-proximal signaling, tumor plasticity, and fibrosis biology. This article translates mechanistic findings on Smad signaling and Sca-1 plasticity into practical assay and interpretation strategies.

• Gepotidacin Mechanism in S. aureus Gyrase

  2026-08-08

  Gibson and colleagues define how gepotidacin, also known as GSK2140944, inhibits Staphylococcus aureus gyrase through a mechanism distinct from fluoroquinolone action. Combining biochemical cleavage assays with two high-resolution crystal structures, the study shows that gepotidacin stabilizes gyrase–DNA complexes and preferentially generates single-stranded rather than double-stranded DNA breaks.

• Carbapenemase Transmission in Enterobacter cloacae

  2026-08-07

  A 2025 BMC Microbiology study characterized carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, China. Its integrated analysis of gene location, plasmid transfer, mobile genetic elements, and strain relatedness shows how blaNDM-1 can disseminate through both horizontal and vertical pathways.

• CB-839 (Telaglenastat): Precision Tool for Cancer Metabolism

  2026-08-07

  CB-839 (Telaglenastat) is redefining cancer metabolism research by enabling highly selective inhibition of glutaminase 1 and robust assessment of glutaminolysis dependency in diverse tumor models. This guide unpacks actionable workflows, advanced troubleshooting, and translational insights, spotlighting the compound's unique value for experimental and preclinical oncology studies.

• Applied Research with YC-1: sGC Activation & HIF-1α Inhibiti

  2026-08-06

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a dual-action small molecule that empowers cancer researchers to dissect hypoxia signaling and angiogenesis with precision. This guide details practical workflows, troubleshooting insights, and unique applications of APExBIO’s high-purity YC-1 to accelerate experimental discovery.

• Cefiderocol’s In Vitro Efficacy Against Resistant P. aerugin

  2026-08-06

  This large-scale European study demonstrates that cefiderocol maintains high in vitro activity against Pseudomonas aeruginosa and Acinetobacter spp., even among isolates resistant to meropenem and modern β-lactam/β-lactamase inhibitor combinations. The findings inform susceptibility testing strategies and underscore the urgent need for robust antibacterial agents targeting multidrug-resistant non-fermenters.

• Single-Dose Gepotidacin for Treating Uncomplicated Gonorrhea

  2026-08-05

  The referenced phase 2 trial demonstrates that single oral doses of Gepotidacin (GSK2140944) achieved ≥95% microbiological cure rates for uncomplicated urogenital gonorrhea. This innovation addresses a pressing need for new antibiotics against drug-resistant Neisseria gonorrhoeae, with clear implications for both clinical practice and antibacterial research.

• AM251: Streamlining CB1 Receptor Antagonist Assays in Resear

  2026-08-05

  AM251 is a nanomolar-potency CB1 receptor antagonist that empowers cannabinoid receptor research with precise modulation of endocannabinoid signaling. This guide translates advanced mechanistic insights into actionable workflows, troubleshooting strategies, and novel applications for metabolic and neuroscience research.

• PPM-18: Precision iNOS Inhibition and the Future of Inflamma

  2026-08-04

  Explore how PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) enables ultra-selective iNOS inhibition and NF-κB pathway modulation for advanced inflammation and sepsis models. This article uniquely bridges mechanistic detail with practical assay design and cross-pathway insights.

• Rifampin in Translational Research: Mechanistic Leverage and

  2026-08-04

  This thought-leadership article explores how Rifampin, a rifamycin antibiotic, uniquely empowers translational researchers to dissect bacterial transcription, resistance mechanisms, and synthetic biology applications. We blend mechanistic detail with strategic guidance, integrate evidence from clinical and experimental studies, and provide actionable protocol parameters for robust, reproducible results. The article also contextualizes APExBIO’s Rifampin within the evolving competitive landscape and projects its future role in antibiotic drug research.

449 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page